What is the 13F Pro Quality Score for TMCI?

13F Pro ranks TREACE MEDICAL CONCEPTS, INC. (TMCI) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View TMCI's current score at https://13fpro.ai/company/TMCI (free sign-up required for the full ranking).

Which hedge funds own the most TMCI stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of TMCI include ARMISTICE CAPITAL,, BANK OF AMERICA /DE/, GAGNON SECURITIES. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/TMCI as soon as new 13F filings post.

Where does 13F Pro source TMCI data?

All TREACE MEDICAL CONCEPTS, INC. fundamentals and ownership data come directly from SEC EDGAR. TREACE MEDICAL CONCEPTS, INC. files with the SEC under CIK 1630627. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is TMCI in?

TREACE MEDICAL CONCEPTS, INC. (TMCI) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is TMCI research updated on 13F Pro?

TMCI's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

TREACE MEDICAL CONCEPTS, INC.(TMCI)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1630627 TMCI stock profile & AI dashboard →

13F Pro Quality Score

25.6/100

Rank #2,659 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

51.3/100

Profitability

12.9/100

Balance Sheet

7.6/100

Earnings Quality

41.8/100

Free Cash Flow

15.6/100

Institutional Flow

7.2/100

Revenue Scale

24.1/100

Dilution Risk

11.2/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why TMCI Scores 26/100

exact factor attribution · 2026-09-11

TMCI's composite is held back by profitability and free cash flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+0.3 pts

51th pct

Earnings quality

-0.8 pts

42th pct

Earnings growth

-1.0 pts

31th pct

Shareholder dilution

-1.9 pts

11th pct

Institutional flow

-2.1 pts

7th pct

Scale

-3.9 pts

24th pct

Capital efficiency

-4.2 pts

8th pct

Free cash flow

-5.2 pts

16th pct

Profitability

-5.6 pts

13th pct

Latest change (2026-08-11): 27 → 23 · ↓ Revenue growth 54→34

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

TMCI Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for TREACE MEDICAL CONCEPTS, INC. (TMCI), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TMCI at 25.6/100 on a 32-signal composite quality model, placing it at rank #2,659 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include institutional flow (7.2) and balance sheet strength (7.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 11.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), TREACE MEDICAL CONCEPTS, INC. reports quarterly revenue of $45.4M, net income of $-15.9M, an operating margin of -33.0%. Top institutional holders of TMCI by reported 13-F value include ARMISTICE CAPITAL, BANK OF AMERICA, GAGNON SECURITIES, based on the most recent SEC filings. TMCI trades on the Nasdaq exchange and files with the SEC under CIK 1630627. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TMCI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for TREACE MEDICAL CONCEPTS, INC. directly from SEC EDGAR. TREACE MEDICAL CONCEPTS, INC.'s 13F Pro composite quality score has ranged between 20 and 37 since 2022, currently 25.6 — a declining long-term trajectory across 64 quarterly and live scoring snapshots.

Revenue

Q2 2026

$45.4M

Net Income

Q2 2026

$-15.9M

Free Cash Flow

Q2 2026

$-6.9M

Operating Margin

Q2 2026

-33.0%

ROIC

Q2 2026

-47.1%

D/E Ratio

Q2 2026

0.87

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+1.6% YoY

$212.7MFY 2025

FY22 $141.8MFY23 $187.1MFY24 $209.4MFY25 $212.7M

Net Income

-5.8% YoY

$-59.0MFY 2025

FY22 $-42.8MFY23 $-49.5MFY24 $-55.7MFY25 $-59.0M

Operating Income

+2.8% YoY

$-54.2MFY 2025

FY22 $-34.8MFY23 $-51.4MFY24 $-55.7MFY25 $-54.2M

EPS (Diluted)

-3.3% YoY

$-0.93FY 2025

FY22 $-0.77FY23 $-0.81FY24 $-0.90FY25 $-0.93

Total Assets

-12.2% YoY

$190.6MFY 2025

FY22 $159.0MFY23 $251.9MFY24 $217.1MFY25 $190.6M

Total Debt

+7.5% YoY

$57.3MFY 2025

FY22 $52.7MFY23 $53.0MFY24 $53.3MFY25 $57.3M

Op. Cash Flow

+57.0% YoY

$-16.0MFY 2025

FY22 $-30.6MFY23 $-34.6MFY24 $-37.2MFY25 $-16.0M

Free Cash Flow

+39.5% YoY

$-29.5MFY 2025

FY22 $-45.5MFY23 $-46.0MFY24 $-48.8MFY25 $-29.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$212.7M +1.6%	$209.4M +11.9%	$187.1M +31.9%	$141.8M +50.2%	$94.4M +64.6%	$57.4M
Net Income	$-59.0M -5.8%	$-55.7M -12.6%	$-49.5M -15.7%	$-42.8M -108.3%	$-20.6M -460.3%	$-3.7M
Operating Income	$-54.2M +2.8%	$-55.7M -8.3%	$-51.4M -47.6%	$-34.8M -111.0%	$-16.5M -2031.0%	$855.0K
EPS (Diluted)	$-0.93 -3.3%	$-0.90 -11.1%	$-0.81 -5.2%	$-0.77 -79.1%	$-0.43 -379.4%	$-0.09
Total Assets	$190.6M -12.2%	$217.1M -13.8%	$251.9M +58.4%	$159.0M +12.9%	$140.8M +236.8%	$41.8M
Total Debt	$57.3M +7.5%	$53.3M +0.6%	$53.0M +0.6%	$52.7M +79.5%	$29.4M -10.4%	$32.8M
Operating Cash Flow	$-16.0M +57.0%	$-37.2M -7.5%	$-34.6M -12.8%	$-30.6M -78.3%	$-17.2M -282.6%	$-4.5M
Free Cash Flow	$-29.5M +39.5%	$-48.8M -5.9%	$-46.0M -1.2%	$-45.5M -128.6%	$-19.9M -257.7%	$-5.6M

Get alerted when TMCI's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for TREACE MEDICAL CONCEPTS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of TMCI

ARMISTICE CAPITAL, LLC
$25.3M6,364,000 sh
BANK OF AMERICA CORP /DE/
$13.2M3,305,100 sh
GAGNON SECURITIES LLC
$12.1M3,029,543 sh
VANGUARD CAPITAL MANAGEMENT LLC
$8.1M2,028,479 sh
Gagnon Advisors, LLC
$6.1M1,534,034 sh
AQR CAPITAL MANAGEMENT LLC
$6.0M1,497,673 sh
BlackRock, Inc.
$5.5M1,380,021 sh
MARSHALL WACE, LLP
$5.3M1,328,592 sh
CIBC Bancorp USA Inc.
$4.8M1,216,044 sh
ACADIAN ASSET MANAGEMENT LLC
$3.7M928,177 sh

Fund	Value	Shares
ARMISTICE CAPITAL, LLC	$25.3M	6,364,000
BANK OF AMERICA CORP /DE/	$13.2M	3,305,100
GAGNON SECURITIES LLC	$12.1M	3,029,543
VANGUARD CAPITAL MANAGEMENT LLC	$8.1M	2,028,479
Gagnon Advisors, LLC	$6.1M	1,534,034
AQR CAPITAL MANAGEMENT LLC	$6.0M	1,497,673
BlackRock, Inc.	$5.5M	1,380,021
MARSHALL WACE, LLP	$5.3M	1,328,592
CIBC Bancorp USA Inc.	$4.8M	1,216,044
ACADIAN ASSET MANAGEMENT LLC	$3.7M	928,177

Companies Similar to TMCI

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

ANGO

ANGIODYNAMICS INC

AI score

Very similar · 4 shared holders

ARMISTICE CAPITAL, LLC WEBER CAPITAL MANAGEMENT LLC /ADV JACOBS LEVY EQUITY MANAGEMENT, INC

OSUR

ORASURE TECHNOLOGIES INC

AI score

Very similar · 5 shared holders

GAGNON SECURITIES LLC Gagnon Advisors, LLC JACOBS LEVY EQUITY MANAGEMENT, INC

LUNG

Pulmonx Corp

AI score

Similar quality profile · 2 shared holders

KOTLER KEVIN JACOBS LEVY EQUITY MANAGEMENT, INC

IRIX

IRIDEX CORP

AI score

Similar quality profile · 1 shared holders

WEBER CAPITAL MANAGEMENT LLC /ADV

Outset Medical, Inc.

AI score

Similar quality profile · 2 shared holders

Catalyst Funds Management Pty Ltd Marquette Asset Management, LLC

ARCT

Arcturus Therapeutics Holdings Inc.

AI score

Similar quality profile · 5 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC Abel Hall, LLC Susquehanna Portfolio Strategies, LLC

KROS

Keros Therapeutics, Inc.

AI score

Similar quality profile · 3 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC Susquehanna Portfolio Strategies, LLC nVerses Capital, LLC

ARAY

ACCURAY INC

AI score

Similar quality profile · 3 shared holders

ARMISTICE CAPITAL, LLC WEBER CAPITAL MANAGEMENT LLC /ADV JACOBS LEVY EQUITY MANAGEMENT, INC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put TMCI on your watchlist

Track score changes the day TREACE MEDICAL CONCEPTS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is TMCI a good stock to buy?

13F Pro's AI-powered analysis of TREACE MEDICAL CONCEPTS, INC. (TMCI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TMCI are available on the TMCI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. TMCI is classified as a small company.

Which hedge funds own TMCI?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TMCI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of TREACE MEDICAL CONCEPTS, INC.'s investment landscape.